Effects of PACAP in UV-A radiation-induced retinal degeneration models in rats

J Mol Neurosci. 2011 Jan;43(1):51-7. doi: 10.1007/s12031-010-9392-3. Epub 2010 Jun 3.

Abstract

The retina is constantly exposed to ultraviolet (UV) light with different wavelengths, which may lead to chronic UV-induced retinal injury. In our previous studies, we have shown the protective effects of pituitary adenylate cyclase activating polypeptide (PACAP) in toxic and ischemic retinal injuries. The aim of the present study was to investigate the effects of PACAP in UV-A-induced retinal lesion. We used diffuse UV-A radiation (315-400 nm) to induce acute retinal damage over a short period of exposure. Using standard histological (morphological and morphometrical) analysis, we assessed the actions of intravitreal PACAP (100 pmol/5 µl) treatment on acute UV-A-induced retinal damage. We measured the thickness of nuclear and plexiform layers as well as the number of cells in the outer nuclear and inner nuclear layers and in the ganglion cell layer. Outer limiting membrane-inner limiting membrane distances in the cross-section of the retina were also examined. Our results show that UV-A light-induced retinal damage led to severe degeneration in the photoreceptor layer, and in the outer and inner nuclear layers. Alteration in the plexiform layers was also observed. We found that post-irradiation PACAP treatment significantly attenuated the UV-A-induced retinal damage. Our results provide the basis for future clinical application of PACAP treatment in retinal degeneration and may have clinical implications in several ophthalmic diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Pituitary Adenylate Cyclase-Activating Polypeptide* / pharmacology
  • Pituitary Adenylate Cyclase-Activating Polypeptide* / therapeutic use
  • Rats
  • Rats, Wistar
  • Retina* / drug effects
  • Retina* / pathology
  • Retina* / radiation effects
  • Retinal Degeneration / drug therapy*
  • Retinal Degeneration / etiology*
  • Retinal Degeneration / pathology
  • Ultraviolet Rays / adverse effects*

Substances

  • Pituitary Adenylate Cyclase-Activating Polypeptide